natgillin/translations-raw huggingface dataset:
Patients who experience a severe decrease of vision (equivalent to 4 lines or more) within one week after treatment should not be re-treated, at least until their vision has completely recovered to pre- treatment level and the potential benefits and risks of subsequent treatment have been carefully considered by the treating physician.
Bolesnicima kojima se vid tjedan dana nakon liječenja znatno pogorša (slabiji vid za 4 ili više redaka) lijek se ne smije ponovno davati, barem dok se vid potpuno ne oporavi do razine prije liječenja, a liječnik koji liječi bolesnika mora prije ponovnog davanja lijeka pažljivo procijeniti očekivanu korist i mogući rizik.
Patients who experience a significant reduction in urinary free cortisol [UFC] levels should continue to receive Signifor for as long as benefit is derived.
Bolesnici kod kojih dođe do značajnog smanjenja u razinama slobodnog kortizola u mokraći [engl. urinary free cortisol, UFC] trebaju nastaviti primati Signifor dokle god od toga imaju koristi.
Patients who experience adverse reactions during treatment should wait for these to resolve before driving or operating machines.
Bolesnici koji razviju nuspojave tijekom terapije ne bi smjeli upravljati vozilima ili raditi na stojevima dok se te nuspojave ne povuku.
Patients who experience dizziness should use caution when driving, cycling or using machines.
Bolesnici koji su iskusili omaglicu, moraju oprezno upravljati automobilom, biciklom i raditi sa strojevima.
Patients who experience febrile netutropeania and/or neutropenic infection should have their docetaxel dose reduced to 60 mg/m2 in all subsequent cycles (see sections 4.4 and 4.8).
Bolesnicima u kojih se pojavi febrilna neutropenija i/ili neutropenijska infekcija, u svim sljedećim ciklusima treba smanjiti dozu docetaksela na 60 mg/m2 (vidjeti dio 4.4 i 4.8).
Patients who experience febrile neutropenia and/or neutropenic infection should have their docetaxel dose reduced to 60 mg/m² in all subsequent cycles (see sections 4.4 and 4.8).
Bolesnicama u kojih se pojavi febrilna neutropenija i/ili neutropenijska infekcija u svim sljedećim ciklusima treba smanjiti dozu docetaksela na 60 mg/m2 (vidjeti dio 4.4 i 4.8).
Patients who experience febrile neutropenia and/or neutropenic infection should have their docetaxel dose reduced to 60 mg/m² in all subsequent cycles (see sections 4.4 and 4.8).
Bolesnicima u kojih se pojavi febrilna neutropenija i/ili neutropenijska infekcija, u svim sljedećim ciklusima treba smanjiti dozu docetaksela na 60 mg/m2 (vidjeti dio 4.4 i 4.8).
Patients who experience Grade 3 or 4 stomatitis should have their dose decreased to 60 mg/m2.
Bolesnicima u kojih se pojavi stomatitis stupnja 3 ili 4 treba smanjiti dozu na 60 mg/m2.
Patients who experience Grade 3 or 4 stomatitis should have their dose decreased to 60 mg/m².
Bolesnicama u kojih se pojavi stomatitis stupnja 3 ili 4 treba smanjiti dozu na 60 mg/m2.
Patients who experience severe diarrhoea should be instructed to consult a healthcare professional urgently.
Bolesnicima koji dobiju jaki proljev potrebno je savjetovati da se hitno obrate zdravstvenom djelatniku.
Patients who experience side effects such as stomach problems, light-sensitive skin reactions or significant changes in the levels of liver enzymes may need to have their dose reduced at least temporarily.
U bolesnika kod kojih se javljaju nuspojave poput problema sa želucem, fotosenzitivne reakcije kože ili značajne promjene u razinama jetrenih enzima potrebno je barem privremeno smanjiti dozu.
Patients who experience such reactions that are considered TRISENOX related must resume treatment only after resolution of the toxic event or after recovery to baseline status of the abnormality that prompted the interruption.
Bolesnici koji osjete takve reakcije koje se smatraju povezane s TRISENOXOM moraju nastaviti liječenje samo nakon rješavanja toksičnih događaja ili nakon oporavka na početno stanje abnormalnosti koje je uzrokovalo prekid liječenja.
Patients who fail to achieve this level of response within the described one month test period should be considered non-responsive and should not receive treatment with Kuvan.
Smatra se da na lijek ne odgovaraju oni bolesnici koji tijekom opisanog jednomjesečnog pokusnog razdoblja liječenja ne uspiju postići ovu razinu odgovora te im Kuvan ne treba primjenjivati.
Patients who failed previous therapy: prior null responders, partial responders and relapsers to interferon and ribavirin therapy
Bolesnici koji nisu odgovorili na prethodnu terapiju: bolesnici koji nisu uopće odgovorili, bolesnici koji su djelomično odgovorili i bolesnici koji su doživjeli relaps na prethodnu terapiju interferonom i ribavirinom
Patients who failed to demonstrate response at Week 6 in GEMINI II were retained in the study and received vedolizumab every four weeks.
Bolesnici koji nisu postigli odgovor u 6. tjednu u ispitivanju GEMINI II zadržani su u ispitivanju te su primali vedolizumab svaka četiri tjedna.
Patients who failed to demonstrate response at Week 6 remained in the study and received vedolizumab every four weeks.
Bolesnici kod kojih nije postignut odgovor na liječenje u 6. tjednu nastavili su ispitivanje, te su primali vedolizumab svaka četiri tjedna.
Patients who failed treatment with Stribild and who had HIV-1 with emergent Stribild resistance substitutions harboured virus that remained susceptible to all PIs, NNRTIs, and most other NRTIs.
Pacijenti u kojih liječenje Stribildom nije bilo uspješno i koji imaju HIV-1 s novonoastalim supstitucijama rezistencije na Stribild, sadrže virus koji je ostao osjetljiv na sve PI-ove, NNRTI-ove i većinu drugih NRTI-ova.
Patients who forget a dose, are advised to take it upon discovery and then resume their usual once- daily dosing schedule.
Bolesnicima koji zaborave jednu dozu, preporučuje se da je primjene čim to primijete te da se nakon toga vrate uobičajenom rasporedu doziranja jednom dnevno.
Patients who had a BRCA mutation and were treated with Lynparza lived on average significantly longer without their disease getting worse than patients who had a BRCA mutation and were treated with placebo (a dummy treatment): 11.2 months versus 4.3 months, respectively.
Bolesnice koje su imale BRCA mutaciju i liječene su lijekom Lynparza, živjele su prosječno značajno dulje bez pogoršanja bolesti u odnosu na bolesnice s BRCA mutacijom koji su liječene placebom (prividnim liječenjem): 11,2 mjeseci u odnosu na 4,3 mjeseca.
Patients who had been randomised to placebo in Period A were assigned to receive Humira 40 mg every week in Period B.
Bolesnicima koji su u razdoblju A bili randomizirani za primanje placeba je u razdoblju B dodijeljeno liječenje lijekom Humira u dozi od 40 mg svaki tjedan.
Patients who had been randomised to placebo in Period A were assigned to receive placebo in Period B.
Bolesnici koji su u razdoblju A bili randomizirani za primanje placeba nastavili su primati placebo i u razdoblju B.
Patients who had received 0 prior VEGF/VEGFR-targeted therapy (%)
Bolesnici koji su prethodno primili 0 terapija usmjerenih na VEGF/VEGFR (%)
Patients who had received 1 prior VEGF/VEGFR-targeted therapy (%)
Bolesnici koji su prethodno primili 1 terapiju usmjerenu na VEGF/VEGFR (%)
Patients who had received prior therapy with bevacizumab or prior systemic anticancer therapy for ovarian cancer (e.g. chemotherapy, monoclonal antibody therapy, tyrosine kinase inhibitor therapy, or hormonal therapy) or previous radiotherapy to the abdomen or pelvis were excluded from the study.
Bolesnice koje su prethodno liječene bevacizumabom ili sustavnom terapijom za liječenje karcinoma jajnika (npr. kemoterapijom, terapijom monoklonskim protutijelom, inhibitorom tirozin kinaze ili hormonskom terapijom) ili radioterapijom abdomena ili zdjelice bile su isključene iz ispitivanja.
Patients who had the following were excluded from the trial: creatinine clearance rates < 50 mL/min, NYHA Class III to IV congestive heart failure, or myocardial infarction within the last 4 months, disease progression during the treatment with a bortezomib-containing regimen, or progression during the first 3 months of initiating treatment with lenalidomide and dexamethasone, or progression at any time during treatment with lenalidomide and dexamethasone if this was the subject’s most recent line of therapy.
Iz ispitivanja su bili isključeni bolesnici sa sljedećim: brzina klirensa kreatinina < 50 ml/min, kongestivno zatajenje srca NYHA razreda III do IV ili infarkt miokarda unutar posljednja 4 mjeseca, progresija bolesti tijekom liječenja režimom koji sadrži bortezomib, ili progresija bolesti tijekom prva tri mjeseca od inicijacije liječenja lenalidomidom i deksametazonom, ili progresija bolesti u bilo kojem trenutku liječenja lenalidomidom ili deksametazonom ako je to bila posljednja linija liječenja.
Patients who have a low or very low risk of recurrence should not receive adjuvant treatment. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.
Bolesnici s niskim ili vrlo niskim rizikom od recidiva ne bi trebali primati adjuvantno liječenje. liječenje odraslih bolesnika s inoperabilnim dermatofibrosarkomom protuberans (DFSP) i odraslih bolesnika s rekurentnim i/ili metastazirajućim DFSP-om koji nisu podobni za kirurški zahvat.
Patients who have a stable platelet count ≥ 50 x 109/l for at least 4 weeks without dose adjustment may, at the discretion of the supervising physician, self-administer Nplate solution for injection.
Bolesnici koji imaju stabilan broj trombocita ≥ 50 x 109/l najmanje 4 tjedna bez prilagodbe doze, mogu sami primijeniti Nplate otopinu za injekciju, pod nadzorom liječnika.
Patients who have achieved complete remission after 2 treatment cycles may receive up to 3 additional cycles of Blincyto if the benefits outweigh the risks for the individual patient.
Bolesnici koji su postigli potpunu remisiju nakon dva ciklusa terapije, mogu primiti do tri dodatna ciklusa lijeka Blincyto ako koristi nadmašuju rizike kod pojedinog bolesnika.
Patients who have all three risk factors for PML (i.e., are anti-JCV antibody positive and have received more than 2 years of TYSABRI therapy, and have received prior immunosuppressant therapy) have a significantly higher risk of PML.
Kod bolesnika koji imaju sva tri čimbenika rizika za PML (npr., koji su pozitivni na anti-JCV protutijela i primali su TYSABRI više od 2 godine, i liječeni su imunosupresivima prije primanja TYSABRIJA), rizik za PML je znatno viši.
Patients who have atrial fibrillation are also at risk of blood clots which can travel to the brain and cause a stroke.
Bolesnici s fibrilacijom atrija također su izloženi riziku od krvnih ugrušaka koji mogu putovati do mozga i uzrokovati moždani udar.
Patients who have been given more ZYPREXA than they should, have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Bolesnici koji su primili više lijeka ZYPREXA nego što su trebali imaju sljedeće simptome: ubrzan rad srca, uznemirenost/agresivnost, poteškoće s govorom, neuobičajene pokrete (osobito lica ili jezika) i sniženu razinu svijesti.
Patients who have been given too much olanzapine have also experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Bolesnici koji su primili previše olanzapina imali su i sljedeće simptome: ubrzano lupanje srca, uznemirenost/agresivnost, teškoće pri govoru, neuobičajene pokrete (posebice lica ili jezika) i smanjenu razinu svijesti .
patients who have developed pure red cell aplasia (reduced or stopped red blood cell production) following treatment with any erythropoietin;
bolesnika koji su razvili čistu aplaziju krvnih stanica (smanjena proizvodnja crvenih krvnih stanica ili prestanak njihove proizvodnje) nakon terapije eritropoetinom;
Patients who have ever had hepatitis B infection will be carefully checked by their doctor for signs of this infection you have ever had heart problems (such as angina, palpitations or heart failure) or breathing problems.
Liječnik će pažljivo nadzirati bolesnike koji su imali infekciju virusom hepatitisa B kako bi uočio moguće znakove infekcije. ako ste ikada imali srčane tegobe (poput angine pektoris, osjećaja lupanja srca ili zatajenja srca) ili dišne tegobe.
Patients who have ever had hepatitis B infection will be carefully checked by their doctor for signs of this infection. you have ever had heart problems (such as angina, palpitations or heart failure) or breathing problems.
Liječnik će pažljivo nadzirati bolesnike koji su imali infekciju virusom hepatitisa B kako bi uočio moguće znakove infekcije. ako ste ikada imali srčane tegobe (poput angine pektoris, osjećaja lupanja srca ili zatajenja srca) ili dišne tegobe.
Patients who have experienced a single clinical event
Bolesnici koji su iskusili pojedinačni klinički događaj
Patients who have experienced anaphylactoid/anaphylactic reactions should be treated with caution when re- administering idursulfase, appropriately trained personnel and equipment for emergency resuscitation (including epinephrine) should be available during infusions.
Posebnu pozornost treba obratiti tijekom ponovne primjene idursulfaze u bolesnika koji su doživjeli anafilaktoidne/anafilaktičke reakcije, tijekom infuzije mora biti dostupno odgovarajuće izvježbano osoblje i oprema za reanimaciju u hitnom slučaju (uključujući epinefrin).
Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors.
Bolesnici koji su imali bronhospazam, akutni rinitis, nosne polipe, angioneurotski edem, urtikariju ili druge reakcije alergijskog tipa nakon uzimanja acetilsalicilne kiseline ili nesteroidnih protuupalnih lijekova (NSAID), uključujući i inhibitore COX-2 (ciklooksigenaze-2).
Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors.
Bolesnici koji su imali bronhospazam, akutni rinitis, nosne polipe, angioneurotski edem, urtikariju ili druge reakcije alergijskog tipa nakon uzimanja acetilsalicilne kiseline ili nesteroidnih protuupalnih lijekova (NSAIL), uključujući i inhibitore COX-2 (ciklooksigenaze-2).
Patients who have experienced severe (Grade 3 or 4) vomiting in previous treatment cycles may require anti- emetic therapy.
Bolesnicima koji su jako povraćali (stupanj 3 ili 4) tijekom prethodnog ciklusa liječenja možda će biti potrebno dati antiemetik.
Patients Who have Failed Previous Therapy
Bolesnici koji nisu odgovorili na prethodnu terapiju
Patients who have failed previous therapy: previous partial responders and relapsers to interferon and ribavirin therapy
Bolesnici koji nisu odgovorili na prethodnu terapiju: bolesnici koji su na prethodnu terapiju interferonom i ribavirinom odgovorili djelomično ili su doživjeli relaps
Patients who have failed to respond to a full and adequate course (at least one year of treatment) of beta-interferon, having had at least 1 relapse in the previous year while on therapy, and at least 9 T2-hyperintense lesions in cranial MRI or at least 1 Gd-enhancing lesion, or patients having an unchanged or increased relapse rate in the prior year as compared to the previous 2 years (n=177 in DEFINE; n=141 in CONFIRM).
Bolesnici koji nisu uspjeli odgovoriti na potpun i odgovarajući tijek (barem godinu dana liječenja) beta-interferona, nakon što su imali barem 1 relaps u prethodnoj godini dok su bili na terapiji, i najmanje 9 T2-hiperintenzivnih lezija u kranijalnoj MR ili barem 1 Gd-pozitivnu leziju, ili bolesnici s nepromijenjenom ili povećanom stopom relapsa u prethodnoj godini u usporedbi s prethodne 2 godine (n=177 u DEFINE; n=141 u CONFIRM).
patients who have had a stroke or a heart attack within the last six months; patients with unstable angina and hereditary eye problems known as ‘retinal degenerative disorders’.
bolesnici koji su imali moždani udar ili srčani udar unutar posljednjih šest mjeseci; bolesnici s nestabilnom anginom ili nasljednim očnim problemima poznatima kao „degenerativni poremećaji mrežnice”.
patients who have had liver transplantation or in
bolesnika kojima je transplantirana jetra ili kod
Patients who have had or are undergoing liver transplantation are at particular risk since the incidence of acute renal failure is high in this group.
Bolesnici kod kojih je transplantirana jetra, odnosno koji će biti podvrgnuti transplantaciji jetre su posebno ugroženi, budući da je u toj skupini bolesnika visoka incidencija akutnog zatajenja bubrega.
patients who have had severe and unexpected reactions to fluoropyrimidine therapy (a group of cancer medicines);
u bolesnika koji imaju ozbiljne i neočekivane reakcije na terapiju fluoropirimidinom (skupinom antikancerogenih lijekova);
patients who have hypotension (low blood pressure);
bolesnici koji imaju hipotenziju (nizak krvni tlak);
Patients who have loss of vision in one eye because of non-arteritic anterior ischemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4).
Bolesnici koji su izgubili vid na jednom oku zbog nearterijske prednje ishemijske optičke neuropatije, bez obzira na to je li ta epizoda povezana s prethodnim izlaganjem inhibitorima PDE5 (vidjeti dio 4.4).
Patients who have poor vision or are blind must be instructed to get assistance from another person when taking Uptravi during the titration period.
Bolesnike koji slabo vide ili su slijepi treba uputiti da zatraže pomoć od druge osobe pri uzimanju Uptravija tijekom razdoblja titracije doze.
Patients who have previously discontinued treatment with tenofovir disoproxil fumarate due to renal toxicity, with or without reversal of the effects post-discontinuation, should not be treated with Stribild (see section 4.3).
Pacijenti koji su prethodno prekinuli liječenje s tenofovirdizoproksilfumaratom zbog bubrežne toksičnosti, s ili bez povratka učinaka nakon prekida primjene lijeka, ne smiju se liječiti Stribildom (vidjeti dio 4.3).
Patients who have previously discontinued treatment with tenofovir disoproxil fumarate due to renal toxicity, with or without reversal of the effects post-discontinuation.
Pacijenti koji su prethodno prekinuli liječenje s tenofovirdizoproksilfumaratom zbog bubrežne toksičnosti, s ili bez povratka učinaka nakon prekida primjene lijeka.
Patients who have previously failed therapy with an NS5A-containing regimen
Bolesnici u kojih je prethodna terapija režimom koji sadrži inhibtor NS5A bila neuspješna
Patients who have previously failed therapy with an NS5A-containing regimen
Bolesnici u kojih je prethodna terapija režimom koji sadrži NS5A bila neuspješna
Patients who have problems with their kidneys should consider a low sodium diet.
Umnažanje je dopušteno samo uz citiranje izvora. imaju problema s bubrezima moraju razmotriti dijetu s niskim sadržajem soli.
Patients who have rapidly evolving severe MS.
Bolesnika koji boluju od teške multiple skleroze koja se brzo razvija.
Patients who have received an allogenic stem cell transplant.
Bolesnici kojima su presađene alogene matične stanice.
Patients who have received taxane and anthracycline- containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Avastin in combination with capecitabine.
Lijekom Avastin u kombinaciji s kapecitabinom ne smiju se liječiti bolesnici koji su u proteklih 12 mjeseci u okviru adjuvantnog liječenja primali taksane ili antracikline.
Patients who have specific mutations of their factor IX gene such as major deletion may be more likely to develop an inhibitor to factor IX and/or experience allergic reactions.
Kod bolesnika koji imaju posebne mutacije gena za faktor IX, kao što su velike delecije, postoji veća vjerojatnost od razvoja inhibitora faktora IX i/ili alergijskih reakcija.
Patients who have specific mutations of their factor IX gene such as major deletion may be more likely to have factor IX inhibitors and an allergic reaction in the early period with any factor IX concentrate.
Za bolesnike koji imaju specifične mutacije svoga gena za faktor IX, kao što su veća delecija (brisanje), vjerojatnije je da će imati inhibitore faktora IX i alergijsku reakciju u ranom razdoblju s bilo kojim koncentratom faktora IX.
Patients who have stopped treatment due to hypersensitivity reactions should not restart therapy with INTELENCE.
Bolesnici koji su prekinuli liječenje zbog reakcija preosjetljivosti ne smiju ponovo započeti terapiju s INTELENCEom.
Patients who have taken more Olanzapine Apotex than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Bolesnici koji su uzeli više Olanzapine Apotexa nego što su trebali imali su sljedeće simptome: ubrzan rad srca, uznemirenost/agresivnost, poteškoće s govorom, neuobičajene pokrete (osobito lica ili jezika) i sniženu razinu svijesti.
Patients who have taken more OLANZAPINE CIPLA than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Bolesnici koji su uzeli više lijeka OLANZAPINE CIPLA nego što su trebali imaju sljedeće simptome: ubrzan rad srca, uznemirenost/agresivnost, poteškoće s govorom, neuobičajene pokrete (osobito lica ili jezika) i sniženu razinu svijesti.
Patients who have taken more Olanzapine Glenmark Europe than they should, have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Bolesnici koji su uzeli više lijeka Olanzapin Glenmark Europe nego što su trebali imaju sljedeće simptome: ubrzani rad srca, uznemirenost/agresivnost, poteškoće s govorom, neuobičajene pokrete (osobito lica ili jezika) i sniženu razinu svijesti.
Patients who have taken more Olanzapine Glenmark than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Bolesnici koji su uzeli više lijeka Olanzapin Glenmark nego što su trebali imaju sljedeće simptome: ubrzani rad srca, uznemirenost/agresivnost, poteškoće s govorom, neuobičajene pokrete (osobito lica ili jezika) i sniženu razinu svijesti.
Patients who have taken more Olanzapine Teva than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Bolesnici koji su uzeli više Olanzapina Teva nego što su trebali imaju sljedeće simptome: ubrzani rad srca, uznemirenost/agresivnost, problemi s govorom, neuobičajeni pokreti (osobito lica ili jezika) i snižena razina svijesti.
Patients who have taken more Olazax Disperzi than they should, have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Bolesnici koji su uzeli više Olazax Disperzi tableta nego što su trebali imaju sljedeće simptome: ubrzani rad srca, uznemirenost/agresivnost, problemi s govorom, neuobičajeni pokreti (osobito lica ili jezika) i snižena razina svijesti.